HCPCS Level II · Outpatient PPS (temporary codes)
C9076Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Terminated 09/30/2021
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About C9076
C9076 is an HCPCS Level II code in the C series (outpatient PPS (temporary codes)), describing lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose.
It was added to HCPCS effective 07/01/2021, and its current record took effect 10/01/2021.
It was terminated on 09/30/2021 and can't be billed for later dates of service.
Its Medicare coverage code is "D", meaning special Medicare coverage instructions apply.
Details
- Short description
- Lisocabtagene car pos t
- Date added
- 07/01/2021
- Action effective
- 10/01/2021
- Termination date
- 09/30/2021
- BETOS
- O1E
Related C90xx codes
Common questions about C9076
Is HCPCS C9076 still valid?
- No. C9076 was terminated on 09/30/2021.
Does Medicare cover C9076?
- Its coverage code is "D": special Medicare coverage instructions apply. Check the local coverage determination for your region.